Research Topics
| Evelina AngovSummaryAffiliation: Walter Reed Army Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Adjustment of codon usage frequencies by codon harmonization improves protein expression and foldingEvelina Angov
Division of Malaria Vaccine Development, Walter Reed Army Institute of Research, Silver Spring, MD, USA
Methods Mol Biol 705:1-13. 2011..Although so far exclusively applied to Escherichia coli, codon harmonization may provide a general strategy for improving the expression of soluble, functional proteins during heterologous host expression...
Marked variation in MSP-119 antibody responses to malaria in western Kenyan highlandsKingsley Badu
Center for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya
BMC Infect Dis 12:50. 2012..An improved understanding of the micro-geographic variation in malaria exposure in the highland ecosystems will be relevant in planning effective malaria control...- Heterologous protein expression is enhanced by harmonizing the codon usage frequencies of the target gene with those of the expression hostEvelina Angov
Molecular Parasitology, Division of Malaria Vaccine Development, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America
PLoS ONE 3:e2189. 2008..Codon harmonization may further provide a general strategy for improving the expression of soluble functional proteins during heterologous expression in hosts other than E. coli... - Codon usage: nature's roadmap to expression and folding of proteinsEvelina Angov
Division of Malaria Vaccine Development, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
Biotechnol J 6:650-9. 2011..Thus, the focus of this review is to provide some experimental support and a brief overview of how codon usage bias has evolved relative to regulating gene expression levels... - Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02AMichele D Spring
United States Military Malaria Vaccine Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America
PLoS ONE 4:e5254. 2009.... - Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responsesJeffrey A Lyon
Division Malaria Vaccine Development, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America
PLoS ONE 3:e2830. 2008..Development of an effective MSP1(42) vaccine against erythrocytic stage P. falciparum infection will depend not only on antigen quality, but also upon the selection of an optimal adjuvant component... - Comparison of Plasmodium berghei challenge models for the evaluation of pre-erythrocytic malaria vaccines and their effect on perceived vaccine efficacyWolfgang W Leitner
Malaria Vaccine Development, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
Malar J 9:145. 2010..Finding shortcomings of both approaches, an alternative approach was explored, i.e., the subcutaneous challenge... - Histidine affinity tags affect MSP1(42) structural stability and immunodominance in miceFarhat Khan
Walter Reed Army Institute of Research, Military Malaria Research Program, Malaria Vaccine Branch, Silver Spring, MD, USA
Biotechnol J 7:133-47. 2012..Thus, the usefulness of protein tags may be outweighed by their potential impact on structure and function, stressing the need for caution in their use. See accompanying commentary by Randolph DOI: 10.1002/biot.201100459... - Cellular and humoral immune effector mechanisms required for sterile protection against sporozoite challenge induced with the novel malaria vaccine candidate CelTOSElke S Bergmann-Leitner
Division of Malaria Vaccine Development, US Military Malaria Vaccine Program, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD 20910, USA
Vaccine 29:5940-9. 2011.... - Immunization with pre-erythrocytic antigen CelTOS from Plasmodium falciparum elicits cross-species protection against heterologous challenge with Plasmodium bergheiElke S Bergmann-Leitner
Division of Malaria Vaccine Development, United States Military Malaria Vaccine Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America
PLoS ONE 5:e12294. 2010..Therefore, targeting the immune response to this highly conserved protein and thus potentially interfering with its biological function may result in protection against infection even by heterologous species of Plasmodium... - Process development and analysis of liver-stage antigen 1, a preerythrocyte-stage protein-based vaccine for Plasmodium falciparumCollette J Hillier
Department of Immunology, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD 20910-7500, USA
Infect Immun 73:2109-15. 2005..Finally, sera taken from people living in a region where malaria is holoendemic recognized LSA-NRC by Western blotting... 
Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccineChristian F Ockenhouse
Department of Immunology, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
Vaccine 24:3009-17. 2006..This study establishes the foundation to further evaluate and measure the vaccine's ability to reduce morbidity and mortality in target populations directly affected by P. falciparum malaria...- Critical evaluation of different methods for measuring the functional activity of antibodies against malaria blood stage antigensElke S Bergmann-Leitner
Department of Immunology, CD and I, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, USA
Am J Trop Med Hyg 75:437-42. 2006..Analysis based on parasitemia and viability was essential for defining the full range of anti-parasite activities in immune sera... - C3d-defined complement receptor-binding peptide p28 conjugated to circumsporozoite protein provides protection against Plasmodium bergheiElke S Bergmann-Leitner
Division of Malaria Vaccine Development, Walter Reed Army Institute of Research, Silver Spring, MD 20910, United States
Vaccine 25:7732-6. 2007..We conclude that use of the CR2-binding motif of C3d as molecular adjuvant to CSP results in anti-malaria protective immune response probably by targeting the chimeric protein to CR2... - A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coliDebabani Roy Chowdhury
Department of Molecular Microbiology and Immunology, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA
PLoS ONE 4:e6352. 2009.... - Evaluation of immunoglobulin purification methods and their impact on quality and yield of antigen-specific antibodiesElke S Bergmann-Leitner
US Military Malaria Vaccine Program, Division of Malaria Vaccine Development, WRAIR, Silver Spring, MD, USA
Malar J 7:129. 2008..Purification of immunoglobulin is a standard approach for reducing such non-specific background activities, but the purification method itself can alter the quality and yield of recovered Ag-specific antibodies... - Molecular adjuvants for malaria DNA vaccines based on the modulation of host-cell apoptosisElke S Bergmann-Leitner
Department of Molecular Parasitology, US Military Malaria Vaccine Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
Vaccine 27:5700-8. 2009..This finding represents yet another example that strategies to enhance vaccine efficacy developed for other model systems such as viral diseases cannot easily be applied to any vaccine... - Impact of pre-existing MSP1(42)-allele specific immunity on potency of an erythrocytic Plasmodium falciparum vaccineElke S Bergmann-Leitner
Malaria Vaccine Branch, US Military Malaria Vaccine Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
Malar J 11:315. 2012..The purpose of this study was to model the effect of pre-existing immunity to MSP142 on the immunogenicity of blood-stage malaria vaccines based on alternative MSP1 alleles... - MSP-1p42-specific antibodies affect growth and development of intra-erythrocytic parasites of Plasmodium falciparumElke S Bergmann-Leitner
US Military Malaria Vaccine Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
Malar J 8:183. 2009..Understanding the mechanisms by which vaccine-induced anti-blood stage antibodies work in protecting against malaria is essential for vaccine design and testing... - Miniaturization of a high-throughput pLDH-based Plasmodium falciparum growth inhibition assay for small volume samples from preclinical and clinical vaccine trialsElke S Bergmann-Leitner
US Military Malaria Vaccine Program, Division of Malaria Vaccine Development, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA
Am J Trop Med Hyg 78:468-71. 2008..This culture method can be extended beyond the pLDH-based readout to other techniques commonly used to determine growth/invasion inhibition... - Molecular vaccines for malariaJoseph T Bruder
GenVec, Inc, Gaithersburg, MD, USA
Hum Vaccin 6:54-77. 2010..In this review, we discuss the molecular aspects of antigen design, adjuvant advancement and the development of vaccine delivery systems as they are being applied to malaria vaccines... - Characterization of a human reference standard for antibody to Plasmodium falciparum merozoite surface protein 1(42)In Kyu Yoon
Division of Communicable Diseases and Immunology, Department of Immunology, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, USA
Am J Trop Med Hyg 72:714-8. 2005..3 microg/mL of MSP-1(42) antibody. This reference standard may be useful as a quantitative working standard for measuring MSP-1(42) antibody response in future vaccine clinical trials involving MSP-1... - Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of ResearchD Gray Heppner
Walter Reed Army Institute of Research, Department of Immunology, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA
Vaccine 23:2243-50. 2005..Recent safety, immunogenicity, and efficacy trials in the US and Africa are presented, as well as plans for the development of a multi-antigen vaccine... - Development and pre-clinical analysis of a Plasmodium falciparum Merozoite Surface Protein-1(42) malaria vaccineEvelina Angov
Department of Immunology, WRAIR, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA
Mol Biochem Parasitol 128:195-204. 2003..FMP1 formulated with GlaxoSmithKline Biologicals (GSK) adjuvant, AS02A or alum was safe and immunogenic in rhesus (Macaca mulatta) monkeys... - C3d binding to the circumsporozoite protein carboxy-terminus deviates immunity against malariaElke S Bergmann-Leitner
Department of Immunology, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
Int Immunol 17:245-55. 2005..We have thus identified C3d-mediated epitope masking and shifting of both the humoral and cellular immune responses as a potential novel escape mechanism, which plasmodia may use to divert the induction of protective immunity... - Activation of innate immunity in healthy Macaca mulatta macaques by a single subcutaneous dose of GMP CpG 7909: safety data and interferon-inducible protein-10 kinetics for humans and macaquesV Ann Stewart
Walter Reed Army Institute of Research, Silver Spring, Maryland, USA
Clin Vaccine Immunol 15:221-6. 2008.... - Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01Nekoye Otsyula
Walter Reed Project, Kenya Medical Research Institute, Kisumu, Kenya
Malar J 12:29. 2013.... - DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunityIlin Chuang
US Military Malaria Vaccine Program, Naval Medical Research Center, Silver Spring, Maryland, United States of America
PLoS ONE 8:e55571. 2013..No subjects with high pre-existing anti-Ad5 neutralizing antibodies were protected but the association was not statistically significant... - Transcutaneous immunization using colonization factor and heat-labile enterotoxin induces correlates of protective immunity for enterotoxigenic Escherichia coliJianmei Yu
Department of Membrane Biochemistry, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA
Infect Immun 70:1056-68. 2002..Overall, our results demonstrate that relevant colonization factor and antitoxin immunity can be induced by TCI and suggest that an ETEC traveler's diarrhea vaccine could be delivered by using a patch... - The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasitesChristian A Darko
Department of Immunology, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD 20910, USA
Infect Immun 73:287-97. 2005..Soluble MSP1(42) (FVO) expressed in E. coli offers excellent promise as a component of a vaccine against erythrocytic-stage falciparum malaria... - Enzyme-linked immunosorbent assay for detection of Plasmodium falciparum histidine-rich protein 2 in blood, plasma, and serumCarolyne M Kifude
Walter Reed Project Kenya Medical Research Institute, Kisumu, Kenya
Clin Vaccine Immunol 15:1012-8. 2008..We conclude that PfHRP2 ELISA using whole-blood and serum samples is a suitable adjunct to microscopy and could ultimately benefit malaria intervention trials... - Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trialMahamadou A Thera
Malaria Research and Training Center, University of Bamako, Bamako, Mali
PLoS ONE 3:e1465. 2008..The objective was to evaluate the safety, reactogenicity and immunogenicity of the AMA-1-based blood-stage malaria vaccine FMP2.1/AS02A in adults exposed to seasonal malaria... - Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western KenyaJose A Stoute
US Army Medical Research Unit and the Kenya Medical Research Institute, Nairobi, Kenya
Vaccine 25:176-84. 2007..16; P<0.001) and the Day 90 responses to MSP-1(42) (F1,335=16.69; P<0.001). The FMP1/AS02A vaccine is safe and immunogenic in adults and should progress to safety testing in children at greatest risk of malaria... - Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alumSathit Pichyangkul
Department of Immunology and Medicine, Armed Forces Research Institute of Medical Science AFRIMS, Bangkok, Thailand
Vaccine 22:3831-40. 2004..The notable difference in Th1/Th2 polarization induced by the AS02A and AS01B formulations warrants comparative clinical testing... - Suramin and suramin analogues inhibit merozoite surface protein-1 secondary processing and erythrocyte invasion by the malaria parasite Plasmodium falciparumSuzanne L Fleck
Medical Research Council Technology, 1-3 Burtonhole Lane, Mill Hill, London NW7 1AD, United Kingdom
J Biol Chem 278:47670-7. 2003..The results indicate that enzymatic events during invasion are suitable targets for drug development and validate the novel concept of an inhibitor binding to a macromolecular substrate to prevent its proteolysis by a protease...